FrancophonIA/ELRC3.0 huggingface dataset:
English: In order to prepare the injection, the content of both vials, once thawed, are mixed and then injected only by a veterinarian directly into the affected joint.
Slovenian: Za pripravo injekcije se po odtalitvi zmeša vsebina obeh vial, ki jo nato neposredno v prizadeti sklep injicira izključno veterinar.
English: Before withdrawing the vials from the liquid nitrogen canister, protective equipment consisting of gloves, long sleeves and a facemask or goggles should be worn.
Slovenian: Pred odvzemom vial iz posode s tekočim dušikom mora oseba nositi zaščitno opremo, ki jo sestavljajo rokavice, dolgi rokavi in obrazna maska oziroma zaščitna očala.
English: EMA/410964/2018
Slovenian: pridobljene iz periferne krvi) EMA/410964/2018
English: In a field study involving horses with a history of lameness lasting 2 to 6 months, 50 horses were treated with Arti-Cell Forte and 25 received a placebo (dummy injection) of saline in one fetlock joint.
Slovenian: V terenski študiji, ki je vključevala konje z anamnezo šepavosti s trajanjem od 2 do 6 mesecev, so 50 konjev zdravili z zdravilom Arti-Cell Forte, 25 pa jih je prejemalo placebo (zdravilo brez učinkovine) s fiziološko raztopino v en bicljev sklep.
English: It contains stem cells which are obtained from equine blood.
Slovenian: Vsebuje matične celice, pridobljene iz konjske krvi.
English: The medicine is available as an injection and can only be obtained with a prescription.
Slovenian: Zdravilo je na voljo v obliki injekcije, njegovo predpisovanje in izdaja pa je le na recept.
English: All horses received intravenous ketoprofen, a medicine to relieve pain and inflammation, at the time of treatment.
Slovenian: Vsi konji so ob času zdravljenja intravensko prejemali ketoprofen, zdravilo za lajšanje bolečin in vnetja.
English: For more information about using Arti-Cell Forte, see the package leaflet or contact your veterinarian or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Arti-Cell Forte glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
English: The most common side effects with Arti-Cell Forte (which may affect more than 1 in 10 horses) are mild increases in lameness, injection site reactions such as swelling and mild increases in temperature at the injection site.
Slovenian: Najpogostejši neželeni učinki zdravila Arti-Cell Forte (ki lahko prizadenejo več kot 1 konja od 10) so blago povečanje šepavosti, reakcije na mestu injiciranja, kot je oteklina, in blago povišanje temperature na mestu injiciranja.
English: The vials containing equine mesenchymal stem cells and equine allogeneic plasma can be stored and transported either frozen or in liquid nitrogen containers.
Slovenian: Viale, ki vsebujejo mezenhimske matične celice in konjsko alogensko plazmo, je treba shranjevati in prevažati v zamrznjeni obliki ali v vsebnikih s tekočim dušikom.
English: Why is Arti-Cell Forte authorised in the EU?
Slovenian: Zakaj je zdravilo Arti-Cell Forte odobreno v EU?
English: This product contains chondrogenic induced equine mesenchymal stem cells and EAP.
Slovenian: To zdravilo vsebuje hondrogeno inducirane konjske mezenhimske matične celice in EAP.
English: An overview of Arti-Cell Forte and why it is authorised in the EU
Slovenian: Pregled zdravila Arti-Cell Forte in zakaj je odobreno v EU
English: What are the risks associated with Arti-Cell Forte?
Slovenian: Kakšna tveganja so povezana z zdravilom Arti-Cell Forte?
English: The withdrawal period for meat from horses treated with Arti-Cell Forte is ‘zero' days, which means that there is no mandatory waiting time.
Slovenian: Karenca za meso konjev, zdravljenih z zdravilom Arti-Cell Forte, je nič dni, kar pomeni, da ni obvezne čakalne dobe.
English: What is Arti-Cell Forte and what is it used for?
Slovenian: Kaj je zdravilo Arti-Cell Forte in za kaj se uporablja?
English: What benefits of Arti-Cell Forte have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Arti-Cell Forte izkazalo v študijah?
English: The stem cells in the active substance (mesenchymal stem cells) are treated so that they develop into cartilage cells.
Slovenian: Matične celice v učinkovini (mezenhimske matične celice) so obdelane tako, da se razvijejo v hrustančne celice.
English: Arti-Cell Forte is a veterinary medicine used to treat mild to moderate lameness linked to non-infective joint inflammation in horses.
Slovenian: Arti-Cell Forte je zdravilo za uporabo v veterinarski medicini, ki se uporablja za zdravljenje blage do zmerne šepavosti, povezane z neinfektivnim vnetjem sklepov, pri konjih.
English: The handling of liquid nitrogen should take place in a wellventilated area.
Slovenian: Delo s tekočim dušikom mora potekati v dobro zračenem prostoru.
English: How does Arti-Cell Forte work?
Slovenian: Kako zdravilo Arti-Cell Forte deluje?
English: How is Arti-Cell Forte used?
Slovenian: Kako se zdravilo Arti-Cell Forte uporablja?
English: Six weeks after treatment 68% of the horses treated with Arti-Cell Forte had a lameness score reduction by 2 or 3 lameness grades compared to none of the horses in the control group.
Slovenian: zdravljenih z zdravilom Arti-Cell Forte, rezultat šepavosti zmanjšal za 2 ali 3 stopnje šepavosti, pri konjih iz kontrolne skupine pa do takega izboljšanja ni prišlo pri nobenem konju.
English: Further information on Hyrimoz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Nadaljnje informacije za zdravilo Hyrimoz so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The proportion of patients who had at least a 75% reduction in symptoms after 16 weeks of treatment was 68% with Hyrimoz and 63% with Humira.
Slovenian: Delež bolnikov, pri katerih so se simptomi po 16 tednih zdravljenja zmanjšali za vsaj 75 %, je bil pri zdravilu Hyrimoz 68 %, pri zdravilu Humira pa 63 %.
English: This means that Hyrimoz is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU.
Slovenian: To pomeni, da je zelo podobno drugemu biološkemu zdravilu („referenčnemu zdravilu“), ki je že odobreno v EU.
English: What measures are being taken to ensure the safe and effective use of Hyrimoz?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Hyrimoz?
English: An overview of Hyrimoz and why it is authorised in the EU
Slovenian: Pregled zdravila Hyrimoz in zakaj je odobreno v EU
English: As for all medicines, data on the use of Hyrimoz are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Hyrimoz stalno spremljajo.
English: Hyrimoz is available as a solution for injection under the skin in a pre-filled syringe or pen and is usually given every 2 weeks.
Slovenian: Zdravilo Hyrimoz je na voljo v obliki raztopine za injiciranje pod kožo v napolnjeni injekcijski brizgi ali peresniku in se običajno daje vsaka dva tedna.
English: What benefits of Hyrimoz have been shown in studies?
Slovenian: Kakšne koristi zdravila Hyrimoz so se pokazale v študijah?
English: Why is Hyrimoz authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Hyrimoz odobreno v EU?
English: Other information about Hyrimoz
Slovenian: Druge informacije o zdravilu Hyrimoz
English: Side effects reported with Hyrimoz are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Hyrimoz, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Hyrimoz have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Hyrimoz upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Hyrimoz is mostly used in adults when their conditions are severe, moderately severe or getting worse, or when patients cannot use other treatments.
Slovenian: Zdravilo Hyrimoz se večinoma uporablja pri odraslih, katerih bolezen je huda ali zmerno huda ali pa se poslabšuje oziroma kadar bolnik ne more prejemati drugega zdravljenja.
English: The company that markets Hyrimoz must provide educational packs for doctors who prescribe the medicine.
Slovenian: Podjetje, ki trži zdravilo Hyrimoz, mora pripraviti izobraževalno gradivo za zdravnike, ki zdravilo predpisujejo.
English: Hyrimoz must not be used in patients with active tuberculosis or other severe infections, or in patients with moderate to severe heart failure (an inability of the heart to pump enough blood around the body).
Slovenian: Zdravilo Hyrimoz se ne sme uporabljati pri bolnikih z aktivno tuberkulozo ali drugimi hudimi okužbami ali pri bolnikih z zmernim do hudim srčnim popuščanjem (stanjem, pri katerem srce ne zmore črpati dovolj krvi po telesu).
English: What is Hyrimoz and what is it used for?
Slovenian: Kaj je zdravilo Hyrimoz in za kaj se uporablja?
English: The active substance in Hyrimoz, adalimumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a substance in the body called tumour necrosis factor (TNF).
Slovenian: Učinkovina zdravila Hyrimoz, adalimumab, je monoklonsko protitelo (vrsta beljakovine), ki je bilo zasnovano tako, da v telesu prepozna snov, imenovano tumorje nekrotizirajoči faktor (TNF), in se veže nanjo.
English: TNF is involved in causing inflammation and is found at high levels in patients with the diseases that Hyrimoz is used to treat.
Slovenian: TNF sodeluje pri povzročanju vnetij in je v visokih koncentracijah prisoten pri bolnikih z boleznimi, za katere se zdravilo Hyrimoz uporablja.
English: All these data were considered sufficient to conclude that Hyrimoz will behave in the same way as Humira in terms of effectiveness and safety in its approved uses.
Slovenian: Vsi ti podatki so bili ocenjeni kot zadostni za zaključek, da se bo zdravilo Hyrimoz pri odobrenih načinih uporabe z vidika učinkovitosti in varnosti vedlo enako kot zdravilo Humira.
English: What are the risks associated with Hyrimoz?
Slovenian: Kakšna tveganja so povezana z zdravilom Hyrimoz?
English: Like other medicines of its class, Hyrimoz may affect the ability of the immune system to fight off infections and cancer, and there have been some cases of serious infections and blood cancers in patients using adalimumab.
Slovenian: Tako kot druga zdravila iz istega razreda tudi zdravilo Hyrimoz lahko vpliva na obrambno sposobnost imunskega sistema proti okužbam in raku; pri bolnikih, ki prejemajo adalimumab, so bili namreč zabeleženi nekateri primeri resnih okužb in krvnega raka.
English: For more information on the use of Hyrimoz in all conditions, including when it can be used in children, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Hyrimoz pri vseh navedenih boleznih, vključno s tem, kdaj se lahko uporablja pri otrocih, glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Other rare serious side effects (which may affect up to 1 in 1,000 people) include failure of bone marrow to produce blood cells, disorder of the nerves, lupus and lupus-like conditions (where the immune system attacks the patient's own tissues, causing inflammation and organ damage), and Stevens-Johnson syndrome (a serious skin condition).
Slovenian: Drugi redki resni neželeni učinki (ki se lahko pojavijo pri največ 1 od 1 000 bolnikov) vključujejo nezmožnost kostnega mozga za proizvodnjo krvnih celic, motnje živčevja, lupus in lupusu podobna obolenja (pri katerih imunski sistem napada bolnikova lastna tkiva, kar povzroča vnetje in poškodbe organov) ter Stevens-Johnsonov sindrom (hudo kožno obolenje).
English: Hyrimoz is a medicine that acts on the immune system and is used to treat the following conditions:
Slovenian: Zdravilo Hyrimoz učinkuje na imunski sistem in se uporablja za zdravljenje naslednjih bolezni:
English: Because Hyrimoz is a biosimilar medicine, the studies on effectiveness and safety of adalimumab carried out with Humira do not all need to be repeated for Hyrimoz.
Slovenian: Zdravilo Hyrimoz je podobno biološko zdravilo, zato študij o učinkovitosti in varnosti adalimumaba, ki so že bile izvedene z zdravilom Humira, z zdravilom Hyrimoz ni treba ponavljati.
English: The reference medicine for Hyrimoz is Humira.
Slovenian: Referenčno zdravilo za zdravilo Hyrimoz je zdravilo Humira.
English: • axial spondyloarthritis (inflammation of the spine causing back pain), including ankylosing spondylitis and when X-ray does not show disease but there are clear signs of inflammation;
Slovenian: • aksialnega spondiloartritisa (vnetja hrbtenice, ki povzroča bolečine v hrbtu), vključno z ankilozirajočim spondilitisom, in kadar rentgenska slika ne kaže poškodb, so pa prisotni očitni znaki vnetja;
English: The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Hyrimoz has a highly similar structure, purity and biological activity to Humira and is distributed in the body in the same way.
Slovenian: Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU glede podobnih bioloških zdravil dokazano, da je zdravilo Hyrimoz po zgradbi, čistosti in biološkem delovanju zelo podobno zdravilu Humira in da se po telesu enako porazdeli.
English: Hyrimoz can only be obtained by prescription and treatment must be started and supervised by a doctor who has experience in the treatment of the diseases for which Hyrimoz is used.
Slovenian: Predpisovanje in izdaja zdravila Hyrimoz je le na recept, zdravljenje z njim pa lahko uvede in nadzoruje le zdravnik, ki ima izkušnje z zdravljenjem bolezni, za katere se zdravilo Hyrimoz uporablja.
English: For the full list of side effects and restrictions with Hyrimoz, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Hyrimoz glejte navodilo za uporabo.
English: For more information about using Hyrimoz, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Hyrimoz glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Therefore, the Agency's view was that, as for Humira, the benefits of Hyrimoz outweigh the identified risks and it can be authorised.
Slovenian: Zato je agencija menila, da koristi zdravila Hyrimoz, enako kot pri zdravilu Humira, odtehtajo znana tveganja in se zdravilo lahko odobri.
English: Hyrimoz contains the active substance adalimumab and is a ‘biosimilar medicine'.
Slovenian: Zdravilo Hyrimoz vsebuje učinkovino adalimumab in je „podobno biološko zdravilo“.
English: In addition, a study in psoriasis has shown that the effects of the medicine are equivalent to those of Humira in this condition.
Slovenian: Poleg tega je študija pri psoriazi pokazala, da so učinki zdravila Hyrimoz pri tej bolezni enakovredni učinkom zdravila Humira.
English: Eye specialists treating uveitis should also take advice from doctors who have experience of using Hyrimoz.
Slovenian: Zdravniki specialisti za očesne bolezni, ki zdravijo uveitis, se morajo posvetovati z zdravniki, ki imajo izkušnje z uporabo zdravila Hyrimoz.
English: In addition Hyrimoz was as effective as Humira in a study involving 465 patients with moderate or severe plaque psoriasis.
Slovenian: Poleg tega je bilo zdravilo Hyrimoz v študiji, ki je vključevala 465 bolnikov z zmerno do hudo psoriazo v plakih, enako učinkovito kot zdravilo Humira.
English: How is Hyrimoz used?
Slovenian: Kako se zdravilo Hyrimoz uporablja?
English: Laboratory studies comparing Hyrimoz with Humira have shown that the active substance in Hyrimoz is highly similar to that in Humira in terms of structure, purity and biological activity.
Slovenian: Laboratorijske študije, v katerih so zdravilo Hyrimoz primerjali z zdravilom Humira, so pokazale, da je učinkovina zdravila Hyrimoz po zgradbi, čistosti in biološkem delovanju zelo podobna učinkovini v zdravilu Humira.
English: How does Hyrimoz work?
Slovenian: Kako zdravilo Hyrimoz deluje?
English: Studies have also shown that giving Hyrimoz produces similar levels of the active substance in the body to giving Humira.
Slovenian: Študije so pokazale tudi, da zdravilo Hyrimoz v telesu vzpostavi podobne ravni učinkovine kot zdravilo Humira.
English: The dose and frequency of injection depends on the condition to be treated and the dose for a child is usually calculated according to the child's weight; because Hyrimoz is only available in doses of 40 mg, it is not suitable for children who need less than a 40-mg dose.
Slovenian: Odmerek in pogostnost injiciranja sta odvisna od zdravljene bolezni, odmerek pri otroku pa se običajno izračuna na podlagi njegove telesne mase.
English: • hidradenitis suppurativa (acne inversa), a long-term skin disease that causes lumps, abscesses
Slovenian: • obolenja hidradenitis suppurativa (inverznih aken), tj. dolgotrajnega obolenja kože, ki povzroča zatrdline, abscese (gnojne tvorbe) in kožne brazgotine;
English: After training, patients or their carers may inject Hyrimoz if their doctor considers it appropriate.
Slovenian: Ker je zdravilo Hyrimoz na voljo samo v odmerkih po 40 mg, ni primerno za otroke, ki potrebujejo odmerek, manjši od 40 mg. Bolniki ali njihovi skrbniki lahko po opravljenem usposabljanju sami injicirajo zdravilo Hyrimoz, če zdravnik meni, da je to zanje primerno.
English: These are rare and an appropriate symptomatic treatment should be administered.
Slovenian: Te so redke in jih je treba ustrezno simptomatično zdraviti.
English: a) the administration of the product to animals will interfere with the implementation of national programmes for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
Slovenian: a) bi uporaba zdravila ovirala izvajanje nacionalnih programov za diagnozo, nadzor ali zatiranje živalskih bolezni ali da bi povzročila težave pri zagotavljanju odsotnosti okuženosti pri živih živalih ali živilih ali drugih proizvodih, pridobljenih iz zdravljenih živali.
English: Duration of immunity: 6 months.
Slovenian: Trajanje imunosti: 6 mesecev
English: A hypersensitivity reaction may occur.
Slovenian: Lahko se pojavi preobčutljivostna reakcija.
English: Date of last renewal: 23/03/2010
Slovenian: Datum zadnjega podaljšanja dovoljenja za promet: 23/03/2010
English: MARKETING AUTHORISATION NUMBER(S) EU/2/99/017/001-006
Slovenian: ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/99/017/001-006
English: Shake well prior to use.
Slovenian: Pred uporabo dobro pretresite.
English: Bovalto Ibraxion can therefore be used as a marker vaccine in association with an appropriate diagnostic test.
Slovenian: Bovalto Ibraxion se lahko torej uporablja kot markersko cepivo v povezavi z ustreznim diagnostičnim testom.
English: 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Slovenian: 4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če jepotrebno)
English: Two injections 21 days apart.
Slovenian: 2 odmerka v razmiku 21 dni.
English: Allow the vaccine to reach a temperature of 15°C-25°C.
Slovenian: Pustite, da se cepivo segreje na 15°C do 25°C.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/
Slovenian: Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/.
English: Administer one dose (2 ml) by subcutaneous injection in the neck (at the front of the shoulder) according to the following regimen:
Slovenian: Injicirajte en odmerek (2 ml) v podkožje v predelu vratu na prednjem delu rame po naslednjem režimu:
English: The excipients, including adjuvants, listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Slovenian: SPC tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št. 470/2009.
English: The vaccination may cause a slight rise in body temperature (less than 1°C) for a transient period (less than 48 hours after injection) without any consequence to the health or performance of the animal.
Slovenian: Cepljenje lahko povzroči rahel dvig telesne temperature (manj kot 1 oC) v prehodnem obdobju (manj kot 48 ur po injiciranju) brez kakršnihkoli posledic za zdravje ali proizvodno sposobnost živali.
English: The injection of the vaccine may cause a transient tissue reaction at the site of injection, which may persist for three weeks and rarely up to five weeks.
Slovenian: Vnos cepiva lahko povzroči prehodno reakcijo tkiva na mestu injiciranja, ki lahko traja do treh tednov in le redko do pet tednov.
English: Laboratoire Porte des Alpes Rue de l'Aviation-69800 Saint Priest France
Slovenian: Laboratoire Porte des Alpes Rue de l'Aviation 69800 Saint Priest FRANCIJA
English: 25 doses (50 ml)
Slovenian: 25 odmerkov (50 ml)
English: Shelf life of the veterinary medicinal product as packaged for sale: 18 months Shelf life after first opening the immediate packaging: 6 hours
Slovenian: Rok uporabnosti zdravila v pakiranju za prodajo: 18 mesecev Rok uporabnosti po prvem odpiranju stične ovojnine: 6 ur.
English: The presence of maternally derived antibodies against infectious bovine rhinotracheitis virus may interfere with the vaccination and requires an appropriate vaccination regimen.
Slovenian: Prisotnost maternalnih protiteles proti virusu kužnega govejega rinotraheitisa lahko vpliva na uspešnost cepljenja, zato je potreben poseben program cepljenja.
English: CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 5 doses (10 ml)
Slovenian: VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ODMERKOV 5 odmerkov (10 ml)
English: The gE gene deletion allows differentiation between animals vaccinated with gE-negative vaccines (anti gE antibody negative, IBR vironeutralising antibody positive) and naturally infected animals (positive to both IBR vironeutralising antibody and anti gE antibody).
Slovenian: gE genska delecija omogoča razlikovanje med živalmi, ki so bile cepljene z gE negativnim cepivom (proti gE protitelesa negativne, IBR vironevtralizirajoča protitelesa pozitivne), in naravno okuženimi živalmi (pozitivne na ena in druga; IBR vironevtralizirajoča protitelesa in proti gE protitelesa).
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 09/03/2000
Slovenian: Datum prve pridobitve dovoljenja za promet: 09/03/2000
English: If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package insert with you.
Slovenian: Če vam je bilo to zdravilo nenamerno injicirano, se takoj posvetujte z zdravnikom, čeprav je bila injicirana le majhna količina, in mu pokažite navodila za uporabo.
English: Type I glass bottles with a Nitrile elastomer closure and sealed with an aluminium cap Cardboard box with 1 or 10 bottles of 5 doses Cardboard box with 1 or 10 bottles of 10 doses Cardboard box with 1 or 10 bottles of 25 doses
Slovenian: Steklenička iz stekla tipa I z zamaškom iz nitrilnega elastomera in aluminijasto zaporko Kartonska škatla z 1 ali 10 stekleničkami s 5 odmerki Kartonska škatla z 1 ali 10 stekleničkami z 10 odmerki Kartonska škatla z 1 ali 10 stekleničkami s 25 odmerki